Tips for Risk Evaluation in Pharmaceutical Fill/Finish Sourcing In this post we focus on the critical decision pharmaceutical companies face regarding their fill/finish needs: whether to rely on a single
In Part 1 of this two-part series we highlighted the characterization and functions of LyoDots® and now in Part 2 we uncover specific LyoDots benefits that can be incorporated in
LyoDots® are a unique miniaturized format of lyophilized reagent that can revolutionize diagnostic device development. In this two-part series we explore how instrument and assay designers can take advantage of
In the latest episode of Executing the Vision, Brad Hunter of Emerge Labs interviews Wayne Woodard, CEO of Argonaut Manufacturing Services, who shares his journey from college athlete to founding a
With an ever increasing need to reduce our carbon footprint, we need to find alternative solutions to our shared challenges, and biotechnology- for all it’s good, must be included. The
Addressing novel modalities create the largest challenges in combination product manufacturing. Challenges in combination product manufacturing must overcome what has traditionally been two different manufacturing disciplines. At Argonaut Manufacturing Services,
Biopharma gains a seamless transition from drug discovery through drug product manufacturing San Diego, CA, June 20, 2024 – Abzena, the leading end-to-end integrated contract and development manufacturing organization (CDMO)
How resilient is your manufacturing strategy in the face of potential disruptions to the pharmaceutical supply chain? As we navigate the complex landscape of aseptic drug product manufacturing, the pursuit
Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities with $45 Million Equity Investment from NewVale Capital and Telegraph Hill Partners Investment strengthens Argonaut’s leadership position in sterile fill
Supporting Orphan Drug Aseptic Fill Finish Rare diseases, also known as orphan diseases, are a group of diverse and often life-threatening conditions that collectively affect a small percentage of the